Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Hodgkin's Disease

Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy

Bone Marrow Transplantation volume 33, pages 1225–1229 (2004)Cite this article

Summary:

Our previously published study showed promising results of autologous stem cell transplantation (ASCT) in patients with primary resistant Hodgkin's disease (HD). Probabilities of overall survival (OS) and progression-free survival (PFS) at 3 years were 55 and 36%, respectively. The present study was undertaken to compare these results with conventionally treated patients and thus evaluate therapeutic options. Retrospective data on 76 adult patients who underwent ASCT were matched with 76 conventionally treated patients from 17 centers. Comparison of clinical characteristics in both groups showed that ASCT patients were younger (24 vs 31.5 years, P=0.001), more frequently presented with ‘B’ symptoms (P=0.03) and that more patients treated with chemotherapy (CT) had elevated LDH (P=0.03). In univariate analyses, bulky disease (P=0.0043) and complete resistance to standard CT (P=0.051) were found to be risk factors for OS. In a multivariate survival analysis only bulky disease was found to an independent prognostic factor (P=0.005). There was no difference in survival between the treatment groups with 5 years OS 33.7 (CI: 23–46) in the ASCT group and 35.6% (CI: 25–50) for the CT group (P=0.92). We conclude that ASCT is not superior to standard CT for treatment of patients with primary refractory HD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Reece DE, Barnett JD, Shepherd DE et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP 16-213 with or without cisplatin (CBV±P) and autologous transplantation for patients with Hodgkin's disease who fail to enter complete remission after combination chemotherapy. Blood 1995; 86: 451–456.

    CAS  PubMed  Google Scholar 

  2. Sweetenham JW, Carella AM, Taghipour G et al. High-dose chemotherapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3101–3109.

    Article  CAS  PubMed  Google Scholar 

  3. Lazarus HM, Rowlings PA, Zhang M-J et al. Autotransplant for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534–545.

    Article  CAS  PubMed  Google Scholar 

  4. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma. Study Group. Blood 2000; 96: 1280–1286.

    CAS  PubMed  Google Scholar 

  5. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent and refractory Hodgkin's disease. Blood 1997; 89: 814–822.

    CAS  PubMed  Google Scholar 

  6. Andre M, Henry-Amar M, Pico J-L et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case–control study. J Clin Oncol 1999; 17: 222–229.

    Article  CAS  PubMed  Google Scholar 

  7. Czyż J, Hellmann A, Dziadziuszko R et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30: 29–34.

    Article  PubMed  Google Scholar 

  8. DeVita Jr VT, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587–595.

    Article  PubMed  Google Scholar 

  9. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528–534.

    Article  CAS  PubMed  Google Scholar 

  10. Ferme C, Mounier N, Divine M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H 89 Trial. J Clin Oncol 2002; 20: 467–475.

    CAS  PubMed  Google Scholar 

  11. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145.

    CAS  PubMed  Google Scholar 

  12. Sureda A, Arranz R, Iriondo A et al. Autologous stem cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Es-panol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404.

    Article  CAS  PubMed  Google Scholar 

  13. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hemato-poietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813.

    CAS  PubMed  Google Scholar 

  14. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704–711.

    Article  CAS  PubMed  Google Scholar 

  15. Gribben JG, Linch DC, Singer CR et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemo-therapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344.

    CAS  PubMed  Google Scholar 

  16. Porter D, Connors J, VanDeerlln V et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999; 17: 1234–1243.

    Article  CAS  PubMed  Google Scholar 

  17. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral- blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical University of Gdansk, Poland

    J Czyz, W Knopinska-Posluszny & A Hellmann

  2. Imperial College School of Medicine, Hammersmith Hospital, London, UK

    R Szydlo

  3. University of Medical Sciences, Poznan, Poland

    J Gozdzik & J Hansz

  4. Copernicus Memorial Hospital, Medical University, Lodz, Poland

    P Smolewski & T Robak

  5. Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland

    M Osowiecki & J Walewski

  6. The Chaim Sheba Medical Center, Tel Hashomer, Israel

    A Avigdor & A Nagler

  7. Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Cracow, Poland

    T Zemelka & M Pawlicki

  8. Regional Centre of Oncology, Bialystok, Poland

    Z Sawicki & M Wojtukiewicz

  9. Silesian Medical University, Katowice, Poland

    L Kachel & J Holowiecki

  10. Medical University of Warsaw, Poland

    G Charlinski & W W Jedrzejczak

Authors
  1. J Czyz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Szydlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Knopinska-Posluszny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Gozdzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Hansz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Smolewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Osowiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Walewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Avigdor
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Zemelka
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Pawlicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Z Sawicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Wojtukiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. L Kachel
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J Holowiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. G Charlinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. W W Jedrzejczak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Czyz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czyz, J., Szydlo, R., Knopinska-Posluszny, W. et al. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 33, 1225–1229 (2004). https://doi.org/10.1038/sj.bmt.1704508

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704508

Keywords

This article is cited by

Search

Advanced search

Quick links